You are on page 1of 22

Vildagliptin in Type 2 Diabetes

Management to Reduce
Cardiovascular Risk : Efficacy
Without Barrier

dr. Eddy Susatyo, SpPD


The Paradigm of Type 2
Diabetes Treatment

Early and Aggressive Treatment


Driven by Target (AIC < 7%)
Early Combinations
Oral agent oral agent
Oral agent insulin
Early and Aggressive Insulin
Treatment

You might also like